Inoviem Scientific & XoNovo enter service-based partnership

Inoviem Scientific, a contract research biotech (CRB), has entered into a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company that is developing a proprietary small molecule for the treatment of neurodegenerative diseases.

This partnership is aimed at generating crucial information concerning XoNovo’s lead compound, XN001 — a patented new chemical entity (NCE) that is an autophagy modulator for the treatment of neurodegenerative diseases.

Under the terms of the agreement, Inoviem will apply its expertise and technological solutions to isolate and identify XN001’s therapeutic targets and elucidate its mode of action.

“There is uncertainty in all drug development processes. We must think anew,” stressed Dr Pierre Eftekhari, founder and president of Inoviem Scientific. “The goal of our collaboration with XoNovo is to provide a therapeutic solution for patients with neurodegenerative diseases.”

“We are excited to collaborate with Inoviem, and, through this partnership, accelerate our technology with the aim of curing neurodegenerative diseases using the exciting novel mechanism of autophagy enhancement,” said Dr Ido Nevo, XoNovo’s CEO.

Financial terms of this service-based partnership were not disclosed.